ARTERIOCYTE MEDICAL SYSTEMS, INC.

ArterioCyte Medical Systems, Inc. is a specialized medical technology firm focused on the design, development, and integration of advanced cardiovascular diagnostic systems. Based in Hopkinton, Massachusetts, the company leverages proprietary sensing and signal processing technologies to enable high-precision hemodynamic monitoring and vascular assessment tools. Their technical expertise includes real-time waveform analysis, non-invasive blood pressure modeling, and embedded medical device software compliant with FDA 21 CFR Part 820 and IEC 62304 standards. ArterioCyte differentiates itself through miniaturized sensor architectures and closed-loop feedback algorithms optimized for clinical environments, particularly in critical care and perioperative settings. No award history is available to infer specific agency engagements or contract patterns. Consequently, there is insufficient data to identify primary federal clients or recurring programmatic relationships. The company’s primary industry focus lies within medical device development and diagnostic instrumentation, though no NAICS codes are available to precisely categorize their market positioning. Their work aligns with the broader biomedical engineering sector, emphasizing innovation in point-of-care diagnostics and patient monitoring systems. ArterioCyte Medical Systems, Inc. operates as a small business entity under a 2L structure and holds no government certifications. The company maintains a localized presence in Massachusetts, with no public indication of multi-site operations or federal contracting infrastructure beyond its headquarters. Its market positioning reflects a niche focus on proprietary medical hardware and software integration, though without documented federal contracts, its footprint in the government procurement landscape remains undefined.